Tarceva News and Research

RSS
Tarceva is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Tarceva is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib, erlotinib hydrochloride, and OSI-774.
Hana Biosciences reports $5.5 million net loss for first-quarter 2010

Hana Biosciences reports $5.5 million net loss for first-quarter 2010

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Results from VeriStrat biomarker analysis of Phase III trial presented at European Lung Cancer Conference

Results from VeriStrat biomarker analysis of Phase III trial presented at European Lung Cancer Conference

OSI Pharmaceuticals announces European Commission's approval of Tarceva for NSCLC

OSI Pharmaceuticals announces European Commission's approval of Tarceva for NSCLC

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

Targeted therapy based on molecular signatures for treating lung cancer

Targeted therapy based on molecular signatures for treating lung cancer

OSI Pharmaceuticals' first-quarter 2010 total revenues increase 14% to $107M

OSI Pharmaceuticals' first-quarter 2010 total revenues increase 14% to $107M

CancerDrugsDirect.com provides customers access to affordable cancer medications

CancerDrugsDirect.com provides customers access to affordable cancer medications

Genentech's Tarceva receives FDA approval as maintenance therapy for advanced NSCLC

Genentech's Tarceva receives FDA approval as maintenance therapy for advanced NSCLC

High OOP costs discouraging many cancer patients from filling prescriptions

High OOP costs discouraging many cancer patients from filling prescriptions

Synta Pharmaceuticals to present posters on STA-9090 and elesclomol at AACR 2010

Synta Pharmaceuticals to present posters on STA-9090 and elesclomol at AACR 2010

Phase II clinical trial of Avastin and Tarceva in patients with glioblastoma multiforme

Phase II clinical trial of Avastin and Tarceva in patients with glioblastoma multiforme

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

Astellas Pharma forms agreement to review certain confidential information of OSI Pharmaceuticals

Astellas Pharma forms agreement to review certain confidential information of OSI Pharmaceuticals

USPTO issues Notice of Allowance for menadione to prevent skin rash in patients taking EGFR inhibitors

USPTO issues Notice of Allowance for menadione to prevent skin rash in patients taking EGFR inhibitors

OSI Pharmaceuticals to redeem outstanding 3.25% Convertible Senior Subordinated Notes due 2023

OSI Pharmaceuticals to redeem outstanding 3.25% Convertible Senior Subordinated Notes due 2023

European CHMP issues positive opinion for Roche's Tarceva as maintenance therapy for NSCLC

European CHMP issues positive opinion for Roche's Tarceva as maintenance therapy for NSCLC

CHMP issues positive opinion recommending approval of Tarceva as monotherapy for NSCLC

CHMP issues positive opinion recommending approval of Tarceva as monotherapy for NSCLC